Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a conference call to discuss the Q2FY24 financial results will be held on Tuesday, 07th November, 2023 at 05.30 p.m. Please find attached herewith the conference call details. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Board Meeting Intimation for Notice Of Meeting Of Board Of Directors Of Alkem Laboratories Limited
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2023. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Please find enclosed herewith the details regarding the voting results of the business transacted through Postal Ballot by remote e-voting process in the prescribed format alongwith the Scrutinizer''s Report. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot
Please find attached herewith the details regarding the voting results of the business transacted through Postal Ballot by remote e-voting process in the prescribed format along with the Scrutinizers Report. Kindly take the same on the report. Alkem Laboratories Ltd - 539523 - Closure of Trading Window
This is to inform you that in terms of Company''s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from 29th September, 2023 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and half year ended 30th September, 2023 are communicated to the Stock Exchanges. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 attached herewith is the details of Analyst/ Institutional Investor meeting to be conducted.
Pharma firm Alkem launches drive to raise awareness about early diagnosis, treatment of respiratory ailments
'Access to prevention and treatment for all. Leave no one behind is the theme of this year's World Lung Day. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to intimate you that the Company and Biosergen AB have entered into a co-development and license agreement for development and commercialization of Biosergen''s novel polyene macrolide antifungal product BSG005 for the treatment of severe invasive fungal disease. A press release in this regard is enclosed herewith. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 attached herewith is the details of Analyst/ Institutional Investor meeting to be conducted. Alkem Laboratories'launches API business
Alkem Activa to supply active pharmaceutical ingredients to drugmakers